MES1022 Drug Conjugate
MES1022 is a drug-conjugate consisting of two parts:
1. the Targeting moiety, and
2. the Drug moiety.
The targeting moiety is a novel proprietary molecule that has high-affinity to bone. The drug moiety is a prostaglandin mimetic that acts on PGE2 receptor 4 (EP4) released from the conjugate with a half-life of 7 days.
How it works
The MES1022 drug-conjugate carries the drug in an inactive state until it binds to the bone. After the targeting moiety binds to bone, the drug is released where it is received by stem cells, stimulating their maturation to osteoblasts (bone-making cells).
How safe is it?
MES1022 avoids systemic exposure and side effects by specifically delivering drugs to the bone.
We have completed GLP toxicity studies in NHPs. It is well tolerated and there were no unexpected toxicity findings.